August 27, 2024CureusOpen Access

Pre-transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-transplant Outcomes: A National Study

View Full Paper

Ask AI

Bookmark

Authors

JDJay DesaiSaint Louis University Hospital RORaymond I OkekeSaint Louis University Hospital RDRoshani DesaiSanjay Ghodawat University

Discussion

Member takes

Implication

Retrospective observational study reveals no significant survival difference with pre-transplant loco-regional therapy in hepatocellular carcinoma, suggesting its safe utility as bridging care.

Key Points

Pre-transplant loco-regional therapy yields no significant five-year survival benefit in hepatocellular carcinoma patients undergoing orthotopic liver transplant.
Adjusted hazard ratio reached 0.97 for single modality and 0.94 for combination loco regional therapy, confirming equivalent survival across recipient cohorts.
Retrospective observational study data from national transplant registries support loco regional therapy as safe bridging care, but prospective trials remain needed.

Cite This Study

Desai et al. (2024) studied this question.

synapsesocial.com/papers/68e5ab93b6db64358754561e https://doi.org/10.7759/cureus.67960

View Full Paper

Ask AI

Bookmark

Implication

Retrospective observational study reveals no significant survival difference with pre-transplant loco-regional therapy in hepatocellular carcinoma, suggesting its safe utility as bridging care.

Pre-transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-transplant Outcomes: A National Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Pre-transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-transplant Outcomes: A National Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider